Skip To Main Content

Benefits of switching to Toujeo® (insulin glargine 300 Units/mL) through patient case studies and patient reported outcomes

T1 Case Studies

T2 Case Studies

Real-World Evidence

Hypoglycaemia is the most frequent adverse reaction observed in clinical trials conducted with Toujeo®.7 Other common adverse effects are lipohypertrophy and injection site reactions.7

For further information on the safety profile of Toujeo® please consult the Summary of Product Characteristics >

1 Colin IM, et al. Diabetes Ther. 2020;11:1835–1847

Toujeo® Summary of Product Characteristics. Available at: www.medicines.ie (Accessed May 2024)

Diabetes Products

Toujeo® Product Page

Click here for Prescribing Information

 

MAT-IE-2300465 (v1.0)
Date of preparation: July 2024

Lantus® Product Page

Click here for Prescribing Information

 

MAT-IE-2300466 (v1.0)
Date of preparation: May 2024

MAT-IE-2300506 (v1.0)
Date of Preparation: May 2024